Frontlight ResearchEarly access
Active, not recruitingPhase 3
Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia
Key facts
- Who runs it
- Taejoon Pharmaceutical Co., Ltd.
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 351 people enrolled
- Started
- 11 Aug 2025
- Expected to end
- 1 Sept 2027
- Type of study
- Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- CTO0308
- Vehicle (Placebo solution)
- Record updated
- 1 September 2026
Who can take part
- Age
- 5 years to 12 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 23 criteriaShow less
Who can take part
- Children aged ≥5 years and ≤12 years at the time of informed consent
- Participants who meet all of the following refractive criteria in both eyes at screening and randomization:; Spherical equivalent (SE) between -1.00 D and -7.00 D
- Participants with myopia progression of ≥0.50 D in both eyes within the past year
- Participants with distance-corrected visual acuity of 0.2 (logMAR) or better in both eyes at screening
- Participants whose parent voluntarily provided written informed consent for participation in the clinical trial (or the participant and one of the participant's parents provided written informed consent)
Who cannot take part
- Participants who have undergone vision correction surgery or procedures
- Participants with ocular surgery within 6 months before screening or planned ocular surgery during the study
- Participants with prior use of atropine eye drops for myopia control before screening
- Participants with prior use of myopia control lenses or spectacles, except those who discontinued due to intolerance or lack of efficacy and completed a ≥12-week washout period
- Participants with a history of hypersensitivity to any component of the investigational product
- Participants with diseases requiring caution with any component of the investigational product, including:; Down syndrome; Voiding dysfunction due to bladder weakness, megacolon, or acute pulmonary edema; History of sensitivity to belladonna alkaloids
- Participants who have undergone organ or bone marrow transplantation
- Participants who received another investigational drug within 30 days before study participation
- Participants with macular degeneration, congenital retinal disease, cataract, or other optic nerve disease affecting vision
- Participants with chronic or recurrent inflammatory ocular disease or active ocular infection
- Participants with Marfan syndrome, Stickler syndrome, retinopathy of prematurity, Ehlers-Danlos syndrome, or progressive retinal atrophy that may cause severe myopia
- Participants with brain disease that may affect visual acuity
- Participants with clinically significant cardiovascular or respiratory disease or spastic paralysis due to brain injury, including cerebral palsy
- Participants with any other disease or condition that, in the investigator's judgment, may affect the efficacy or safety assessment or make the participant unsuitable for the study
- Participants with impaired binocular or stereoscopic vision
- Participants with corneal abnormalities that may interfere with visual acuity assessment, including corneal opacity, scarring, dystrophy, or dysplasia
- Participants who require or are expected to require contact lens use during the study
- Participants who were born prematurely or with low birth weight, unless currently above the normal range according to growth charts
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study was to evaluate the superiority of the myopia progression control effect in the treatment group compared with the control group, evaluated by the change in spherical equivalent (SE) after 12 months of administration of the investigational product.
The 4 groups in the trial
- CTO0308-ATreatment being tested
Ophthalmic solution
Treatment: CTO0308
- CTO0308-BTreatment being tested
Ophthalmic solution
Treatment: CTO0308
- CTO0308-CTreatment being tested
Ophthalmic solution
Treatment: CTO0308
- CTO0308-DPlacebo, for comparison
Vehicle
Treatment: Vehicle (Placebo solution)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-design, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of CTO0308 in Pediatric Patients With Myopia
- Record updated
- 1 September 2026